- Home
- FHTX vs VNDA Comparison
FHTX vs VNDA Comparison
Compare FHTX & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FHTX | VNDA |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.4M | 361.4M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FHTX | VNDA |
|---|---|---|
| Price | $5.40 | $5.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $11.50 | ★ $14.90 |
| AVG Volume (30 Days) | 376.3K | ★ 858.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.32 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $30,909,000.00 | ★ $216,105,000.00 |
| Revenue This Year | $8.89 | $21.35 |
| Revenue Next Year | $20.13 | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.75 | 8.72 |
| 52 Week Low | $3.27 | $4.14 |
| 52 Week High | $6.95 | $9.91 |
Technical Indicators
Market Signals| Indicator | FHTX | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.26 | 42.19 |
| Support Level | $5.22 | $5.67 |
| Resistance Level | $5.70 | $6.67 |
| Average True Range (ATR) | 0.48 | 0.21 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 57.15 | 13.45 |
Price Performance
Historical ComparisonAbout FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.